Drug resistance and drug combination features of the human immunodeficiency virus inhibitor, BCH-10652 [(±)-2'-deoxy-3'-oxa-4'-thiocytidine, dOTC]

Antiviral Chemistry and Chemotherapy

Volumn 11, Issue 4, 2000, Pages 291-301

  Taylor, Debra L ^a   Ahmed, Parvin S ^a   Tyms, A Stanley ^a   Wood, Lara J ^a   Kelly, Lisa A ^a   Chambers, Philip ^a   Clarke, John ^c   Bedard, Jean ^b   Bowlin, Terry L ^b   Rando, Robert F ^b  

^a Virogen Drug Discovery Ltd   (United Kingdom)

^b Shire Canada   (Canada)

^c IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

Author keywords

Anti HIV 1 activity; Drug combination; Drug resistance; Heterosubstituted nucleoside analogue

Indexed keywords

2' DEOXY 3' OXA 4' THIOCYTIDINE; 2' DEOXY 3' OXATHIOCYTIDINE; ADEFOVIR; ANTIGEN P24; ANTIRETROVIRUS AGENT; ARGININE; DIDANOSINE; DOTC; INDINAVIR; ISOLEUCINE; LAMIVUDINE; LYSINE; METHIONINE; NEVIRAPINE; NUCLEOSIDE ANALOG; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; UNCLASSIFIED DRUG; ZIDOVUDINE;

AMINO ACID SUBSTITUTION; ANTIVIRAL ACTIVITY; ARTICLE; CODON; COMPUTER PROGRAM; ENANTIOMER; GENOTYPE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MONONUCLEAR CELL; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; T LYMPHOCYTE; VIRUS MUTANT;

EID: 0033854232     PISSN: 09563202     EISSN: None     Source Type: Journal    
DOI: 10.1177/095632020001100405     Document Type: Article

References (32)

1. + T cell homeostasis and function in advanced HIV disease. Science 277:112-116.
2. Back NKT, Nijhuis M, Keulen W, Boucher CAB, Oude Essink BB, Van Kuilenburg ABP, Van Gennip AH & Berkhout B (1996) Reduced replication of 3TC-resistant HIV-1 variants in primary cells due to a processivity defect of the reverse transcriptase enzyme. European Molecular Biology Organization Journal 15:4040-4049.
3. Belleau B, Brasili L, Chan L, DiMarco M, Zacharie B & Nguyen-Ba N (1993) A novel class of 7,3-oxathiolanucleotide analogues having potent anti-HIV activity. Bioorganic and Medicinal Chemistry Letters 3:1723-1728.
4. Boucher CAB, Cammack N, Schipper P, Schuurman P, Rouse P, Wainberg MA & Cameron JM (1993) High level resistance to (-) enantiomeric 2′-deoxy-3′-thiacytidine in vitro is due to one amino acid substitution in the catalytic site of human immunodeficiency virus type 1 reverse transcriptase. Antimicrobial Agents and Chemotherapy 37:2231-2234.
5. Cameron JM, Colis P, Daniel M, Storer R & Wilcox P (1993) Lamivudine. Drugs of the Future 18:319-323.
6. Carpenter CC, Cooper DA, Fischl MA, Gatell JM, Gazzard BG, Hammer SM, Hirsch MS, Jacobsen DM, Katzenstein DA, Montaner JS, Richman DD, Saag MS, Schechter M, Schooley RT, Thompson MA, Vella S, Yeni PG & Volberding PA (2000) Antiretroviral therapy in adults: updated recommendations of the International AIDS Society - USA Panel. Journal of the American Medical Association 283:381-390.
7. Coates JAV, Cammack N, Jenkinson HJ, Jowett HJ, Jowett MI, Pearson BA, Penn CR, Rouse PL, Viner KC & Cameron JM (1992a) (-)-2′-deoxy-3′-thiacytidine is a potent, highly selective inhibitor of human immunodeficiency virus type 1 and type 2 replication in vitro. Antimicrobial Agents and Chemotherapy 36:733-739.
8. Coates JAV, Cammack N, Jenkinson HJ, Mutton IM, Pearson BA, Storer R, Cameron JM & Penn CR. (1992b) The separated enantiomers of 2′-deoxy-3′-thiacytidine (BCH 189) both inhibit human immunodeficiency virus replication in vitro. Antimicrobial Agents and Chemotherapy 36:202-205.
9. De Muys JM, Gourdeau H, Nguyen-Ba N, Taylor DL, Ahmed PS, Mansour T, Locas C, Richard N, Wainberg MA & Rando R (1999) Anti-HIV efficacy, toxicity, intracellular metabolism and pharmacokinetic evaluation of dOTC (2′-deoxy-3′-oxa-4′-thiocytidine). Antimicrobial Agents and Chemotherapy 43:1835-1844.
10. Gu Z, Gao Q, Fang H, Salomon H, Parniak MA, Goldberg E, Cameron J & Wainberg MA (1994) Identification of a mutation at codon 65 in the IKKK motif of reverse transcriptase that encodes human immunodeficiency virus resistance to 2′,3′-dideoxycytidine and 2′,3′-dideoxy-3′-thiacytidine. Antimicrobial Agents and Chemotherapy 38:275-281.
11. Gu Z, Salomon H, Cherrington JM, Mulato AS, Chen MS, Yarchoan R, Foli A, Sogocio KM & Wainberg M (1995a) K65R mutation of the human immunodeficiency virus type 1 reverse transcriptase encodes cross-resistance to 9-(2-phosphonylmethoxyethyl) adenine. Antimicrobial Agents and Chemotherapy 39:1888-1891.
12. Gu Z, Arts EJ, Parniak MA & Wainberg MA (1995b) Mutated K65R reverse transcriptase of human immunodeficiency virus type 1 shows diminished chain termination in the presence of 2′,3′-dideoxycytidine 5′-triphosphate and other drugs. Proceedings of the National Academy of Sciences, USA 92:2760-2764.
13. Gulick RM, Mellors JW, Havlir D, Eron JJ, Gonzalez C, McMahon D, Richman DD, Valentine FT, Jonas L, Meibohm A, Emini EA & Chodakewitz JA (1997) Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. New England Journal of Medicine 337:734-739.
14. Hammer SM, Squires KE, Hughes MD, Grimes JM, Demeter LM, Currier JS, Eron JJ Jr, Feinberg JE, Balfour HH Jr, Deyton LR, Chodakewitz JA & Fischl MA (1997) A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. New England Journal of Medicine 337:725-733.
15. Kinchington D, Gee S, Balzarini J, Gait M, De Clercq E & Field H (2000) Current antiviral agents factfile: 1999-2000 Update. International Antiviral News 8:4-21.
16. Larder BA, Kemp SD & Harrigan PR (1995) Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy. Science 269:696-699.
17. Mansour TS, Jin H, Wang W, Dixit DM, Evans CA, Tse HLA, Belleau B, Gillard JW, Hooker EU, Ashman C, Cammack N, Salomon H, Belmonte AR & Wainberg MA (1995a) Structure-activity relationships among a new class of antiviral heterosubstituted 2′,3′-dideoxynucleoside analogues. Nucleosides & Nucleotides 14:627-635.
18. Mansour TS, Jin H, Wang W, Hooker EU, Ashman C, Cammack N, Salomon H, Belmonte AR & Wainberg MA (1995b) Anti-human immunodeficiency virus and anti-hepatitis-B virus activities and toxicities of the enantiomers of 2′-deoxy-3′-oxa-4′-thiocytidine and their 5-fluoro analogues in vitro. Journal of Medicinal Chemistry 38:1-4.
19. Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, Aschman DJ, & Holmberg SD (1998) Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. New England Journal of Medicine 338:853-860.
20. Prichard MN & Shipman C (1990) A three-dimensional model to analyse drug-drug interactions. Antiviral Research 14:181-206.
21. Prichard MN, Prichard LE & Shipman C (1993) Strategic design and three-dimensional analysis of antiviral drug combinations. Antimicrobial Agents and Chemotherapy 37:540-545.
22. th Conference on retroviruses and opportunistic infections. Chicago, Ill., USA. Abstract 595.
23. Richard N, Quan Y, Salomon H, Hsu M, Bedard J, Harrigan PR, Rando R, Mansour T, Bowlin TL & Wainberg M (1999) Selection and characterisation of HIV-1 variants resistant to the (+) and (-) enantiomers of 2′-deoxy-3′-oxa-4′-thiocytidine (dOTC). Antiviral Therapy 4:171-177.
24. Schinazi R, Larder B & Mellors J (1999) Mutations in retroviral genes associated with drug resistance: 1999-2000 update. International Antiviral News 5:129-142.
25. Shafer RW, Kozal MJ, Winters MA, Iversen AKN, Katzenstein DA, Ragni MV, Meyer WA, Gupta P, Rasheed S, Coombs R, Katzman M, Fiscus S & Merigan TC (1994) Combination therapy with zidovudine and didanosine selects for drug-resistant human immunodeficiency virus type 1 strains with unique patterns of pol gene mutations. Journal of Infectious Diseases 169:722-729.
26. Shirasaka T, Kavlick MF, Ueno T, Gao W-Y, Kojima E, Alcaide ML, Chokekijchai S, Roy BM, Arnold E, Yarchoan R & Mitsuya H (1995) Emergence of human immunodeficiency virus type 1 variants with resistance to multiple dideoxynucleosides in patients receiving therapy with dideoxynucleosides. Proceedings of the National Academy of Sciences, USA 92:2398-2402.
27. Stoddart CA, Moreno ME, Linquist-Stepps VD, Bare C, Bogan MR, Gobbi A, Buckheit RW Jr, Bedard J, Rando R & McCune JM (2000) Antiviral activity of 2′-deoxy-3′-oxa-4′-thiocytidine (BCH-10652) against lamivudine-resistant human immunodeficiency virus type 1 in SCID-hu Thy/Liv mice. Antimicrobial Agents and Chemotherapy 44:783-786.
28. Stuyver L, Wyseur A, Rombout J, Louwagie T, Scarceq C, Verhofstede D, Rimland RF, Schinazi RF & Rossau R (1997) Line probe assay for rapid detection of drug-selected mutations in the human immunodeficiency virus type 1 reverse transcriptase gene. Antimicrobial Agents and Chemotherapy 41:284-291.
29. Taylor DL, Ahmed PS, Brennan TM, Nave J-F, Casara P & Tyms AS (1996) Anti-HIV activity of MDL 74,968, a novel acyclonucleotide derivative of guanine: drug resistance and drug combination effects in vitro. Antiviral Chemistry and Chemotherapy 7:253-260.
30. Taylor DL, Ahmed PS, Brennan TM, Bridges CG, Tyms AS, Van Dorsselaer V, Tarnus C, Hornsperger J-M & Schirlin D (1997) Anti-human immunodeficiency virus activity, bioavailability and drug resistance profile of the novel proteinase inhibitor MDL 74,695. Antiviral Chemistry and Chemotherapy 8:205-214.
31. Tisdale M, Alnadaf T & Cousens D (1997) Combination of mutations in human immunodeficiency virus type 1 reverse transcriptase required for resistance to the carbocyclic nucleoside 1592U89. Antimicrobial Agents and Chemotherapy 41:1094-1098.
32. Wainberg MA, Salomon H, Gu Z, Montaner JSG, Cooley TP, McCaffrey R, Ruedy J, Hilary MH, Cammack N, Cameron JM & Nicholson W (1995) Development of HIV-1 resistance to (-)-2′-deoxy-3′thiacytidine in patients with AIDS or advanced AIDS-related complex. AIDS 9:351-357.